Spain

The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), operating under the Ministry of Health, is the primary regulatory authority responsible for the authorization, supervision, and pharmacovigilance of medicines, medical devices, diagnostics, and digital health products in Spain. The overarching legislative framework includes Royal Decree-Law 1/2015 (consolidated text of the Law on Guarantees and Rational Use of Medicines and Health Products), Royal Decree 192/2023 (transposing EU MDR 2017/745 and IVDR 2017/746 into national law), and Ley 14/1986 (General Health Law). Pharmaceutical products may follow the EMA centralized procedure, the mutual recognition procedure (MRP), the decentralized procedure (DCP), or a purely national procedure, with AEMPS acting as reference or concerned member state. Medical devices and in-vitro diagnostics are regulated under the EU MDR and IVDR frameworks, requiring CE marking and registration in the national RSMD (Registro de Productos Sanitarios) database administered by AEMPS.

For pharmaceutical submissions, Spain accepts dossiers in Common Technical Document (CTD) format, aligned with ICH guidelines, and requires a locally designated EU-based Marketing Authorization Holder (MAH) or a legal representative established within the European Economic Area. Post-Brexit, UK-issued approvals are not automatically recognized and must follow standard EU pathways. AEMPS has undertaken significant digital transformation reforms under its 2022-2025 strategic plan, including the digitalization of submission portals and the streamlining of variation procedures. For medical devices, economic operators must register with AEMPS and comply with post-market surveillance obligations under MDR/IVDR. Digital health solutions (Software as a Medical Device, SaMD) are assessed according to MDCG guidance and may require CE marking depending on their intended purpose and risk classification. Spain has also adopted the EU Health Technology Assessment (HTA) Regulation 2021/2282, which will progressively harmonize joint clinical assessments at the EU level from 2025 onward, with national added-value assessments continuing to be conducted by domestic bodies.

Public procurement of health products in Spain operates within a decentralized structure shaped by the country's 17 autonomous communities (comunidades autonomas), each of which manages its own health service (servicio de salud) with significant purchasing autonomy. At the national level, the Ministry of Health coordinates overarching policy through the Consejo Interterritorial del Sistema Nacional de Salud (CISNS) and the inter-regional framework agreements, but does not conduct centralized national tenders for most product categories. Aggregated or coordinated procurement initiatives have been developed through bodies such as the Central de Compras del Sector Publico Estatal and, increasingly, through inter-community purchasing consortia. Public tenders are governed by Ley 9/2017 de Contratos del Sector Publico (Law on Public Sector Contracts), which transposes EU Directives 2014/24/EU and 2014/25/EU, mandating open, transparent competitive procedures for contracts above defined thresholds. Pricing and reimbursement of pharmaceuticals are centrally determined by the Comision Interministerial de Precios de los Medicamentos (CIPM), with mandatory reference pricing and positive list inclusion required for public funding. Health technology assessment for reimbursement decisions is supported by the Red Espanola de Agencias de Evaluacion de Tecnologias Sanitarias (RedETS), coordinating HTA activities across national and regional agencies.

The private healthcare sector in Spain represents approximately 30% of total health expenditure and constitutes a meaningful parallel procurement channel, accessed through private hospital groups, mutual insurance societies (mutuas), and direct patient payment. Private procurement follows standard commercial negotiation rather than public tender rules, offering faster market entry pathways for innovative products. Spain does not rely substantially on multilateral donor-funded procurement mechanisms such as UNICEF Supply Division, the Global Fund, Gavi, or USAID, given its status as a high-income country and self-financing national health system. However, Spanish institutions and procurement bodies may participate in joint EU-level procurement mechanisms, including the EU Joint Procurement Agreement (JPA) activated for pandemic countermeasures, vaccines, and medical countermeasures under Health Emergency Preparedness and Response Authority (HERA) frameworks. Local manufacturing preference policies are not formally embedded in Spanish procurement law beyond standard EU state aid constraints, though national industrial strategy documents and EU pharmaceutical strategy initiatives increasingly emphasize supply chain resilience and domestic production capacity for critical medicines and health products.